Penumbra (NYSE:PEN) Hits New 12-Month High After Analyst Upgrade

Penumbra, Inc. (NYSE:PEN)’s share price reached a new 52-week high during trading on Thursday after Truist Financial raised their price target on the stock from $312.00 to $370.00. Truist Financial currently has a buy rating on the stock. Penumbra traded as high as $320.00 and last traded at $311.6410, with a volume of 50844 shares changing hands. The stock had previously closed at $309.26.

Other research analysts have also issued research reports about the stock. Royal Bank Of Canada reiterated an “outperform” rating and set a $355.00 price objective on shares of Penumbra in a research note on Wednesday. Needham & Company LLC increased their price target on Penumbra from $326.00 to $388.00 and gave the company a “buy” rating in a research note on Wednesday. Wells Fargo & Company assumed coverage on Penumbra in a research note on Tuesday, November 18th. They issued an “underweight” rating on the stock. Canaccord Genuity Group upped their price objective on Penumbra from $355.00 to $359.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Robert W. Baird set a $345.00 target price on Penumbra in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $333.47.

Insiders Place Their Bets

In other Penumbra news, Director Harpreet Grewal sold 100 shares of the company’s stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $292.98, for a total transaction of $29,298.00. Following the completion of the sale, the director directly owned 8,416 shares of the company’s stock, valued at approximately $2,465,719.68. This represents a 1.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Johanna Roberts sold 300 shares of Penumbra stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $300.13, for a total transaction of $90,039.00. Following the completion of the transaction, the executive vice president directly owned 63,836 shares in the company, valued at approximately $19,159,098.68. This trade represents a 0.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 34,744 shares of company stock worth $10,387,474. Company insiders own 4.20% of the company’s stock.

Key Penumbra News

Here are the key news stories impacting Penumbra this week:

• Positive Sentiment: JPMorgan upgraded PEN from Neutral to Overweight and bumped its target to $370 (from $275), signaling stronger conviction in Penumbra’s growth trajectory and implying meaningful upside vs. the current share level. JP Morgan Upgrades Penumbra (PEN)
• Positive Sentiment: Truist raised its price target to $370 from $312 and reiterated a Buy, reinforcing the bullish view and matching JPMorgan’s $370 target that implies roughly mid‑teens upside from current levels. Penumbra upgraded to overweight from neutral at JPMorgan
• Positive Sentiment: Additional price-target lifts from RBC (to $355 from $325) and Canaccord (to $359 from $355) add to the consensus upward drift in sell‑side expectations. These moves tighten the buy-side narrative around recurring CAVT adoption and international growth. Penumbra price target raised to $359 from $355 at Canaccord Penumbra price target raised to $355 from $325 at RBC Capital
• Positive Sentiment: Needham reiterated a Buy rating, supporting the positive analyst tone and reducing near‑term downside risk from the sell‑side. Needham maintains Penumbra (PEN) buy recommendation
• Positive Sentiment: Clinical/outcomes coverage: a published evaluation of Penumbra’s CAVT in intermediate‑risk pulmonary embolism (PE) patients highlights outcomes and resource‑utilization benefits—supportive evidence for broader clinical adoption and reimbursement discussions. Penumbra’s CAVT Evaluated for Outcomes and Resource Utilization in Intermediate-Risk PE Patients
• Neutral Sentiment: Media/awareness: Bloomberg’s healthcare segment highlighted Penumbra’s efforts to expand CAVT awareness—positive for long‑term market penetration but more of a brand/voice play than an immediate revenue driver. Vanguards of Health Care: Penumbra Expands CAVT Awareness

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Mather Group LLC. acquired a new stake in Penumbra during the 3rd quarter worth about $25,000. Newbridge Financial Services Group Inc. acquired a new position in shares of Penumbra in the 2nd quarter valued at about $30,000. Rothschild Investment LLC acquired a new position in shares of Penumbra in the 3rd quarter valued at about $40,000. Parkside Financial Bank & Trust lifted its position in shares of Penumbra by 70.2% in the second quarter. Parkside Financial Bank & Trust now owns 160 shares of the company’s stock worth $41,000 after purchasing an additional 66 shares in the last quarter. Finally, Covestor Ltd boosted its holdings in shares of Penumbra by 53.0% during the third quarter. Covestor Ltd now owns 179 shares of the company’s stock worth $46,000 after purchasing an additional 62 shares during the period. 88.88% of the stock is owned by institutional investors and hedge funds.

Penumbra Price Performance

The stock’s 50-day moving average is $274.47 and its 200 day moving average is $260.85. The stock has a market capitalization of $12.37 billion, a PE ratio of 75.59, a P/E/G ratio of 2.60 and a beta of 0.66. The company has a quick ratio of 4.18, a current ratio of 6.73 and a debt-to-equity ratio of 0.02.

Penumbra (NYSE:PEN) last released its earnings results on Wednesday, November 5th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.07. Penumbra had a net margin of 12.30% and a return on equity of 11.35%. The company had revenue of $354.69 million during the quarter, compared to the consensus estimate of $340.77 million. During the same quarter in the prior year, the firm earned $0.85 EPS. The company’s revenue was up 17.8% compared to the same quarter last year. As a group, equities analysts predict that Penumbra, Inc. will post 3.67 earnings per share for the current year.

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.